Similar articles for PMID: 20421772

Year	Number of Results
2003	1
2005	12
2006	4
2007	8
2008	7
2009	7
2010	8
2011	12
2012	9
2013	6
2014	8
2015	3
2017	1
2019	2
2020	1
2021	1
2024	0

1

Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer.

Spitaleri G, Delmonte A, Toffalorio F, De Pas TM, Gregorc V. Spitaleri G, et al. J Thorac Oncol. 2010 May;5(5):752-4. doi: 10.1097/JTO.0b013e3181d6b8a1. J Thorac Oncol. 2010. PMID: 20421772 Free article. No abstract available.

2

Lung cancer response to gefitinib, then erlotinib, then gefitinib again.

Wong AS, Seto KY, Chin TM, Soo RA. Wong AS, et al. J Thorac Oncol. 2008 Sep;3(9):1077-8. doi: 10.1097/JTO.0b013e318183afb0. J Thorac Oncol. 2008. PMID: 18758318 Free article. No abstract available.

3

Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.

Gridelli C, Maione P, Galetta D, Rossi A. Gridelli C, et al. J Thorac Oncol. 2007 Jan;2(1):96-8. doi: 10.1097/JTO.0b013e31802bffb0. J Thorac Oncol. 2007. PMID: 17410020 Free article. No abstract available.

4

Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.

Pennell NA, Yin L, Keshtgarpour M, Ma PC. Pennell NA, et al. J Thorac Oncol. 2012 Jul;7(7):1200-1. doi: 10.1097/JTO.0b013e318250ed89. J Thorac Oncol. 2012. PMID: 22706608 Free article. No abstract available.

5

Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.

Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M, Heigener D. Reck M, et al. J Thorac Oncol. 2010 Oct;5(10):1616-22. doi: 10.1097/JTO.0b013e3181f1c7b0. J Thorac Oncol. 2010. PMID: 20736854 Free article. Clinical Trial.

6

Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.

Vasile E, Tibaldi C, Chella A, Falcone A. Vasile E, et al. J Thorac Oncol. 2008 Aug;3(8):912-4. doi: 10.1097/JTO.0b013e318180275e. J Thorac Oncol. 2008. PMID: 18670311 Free article.

7

Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.

Gridelli C, Maione P, Galetta D, Colantuoni G, Del Gaizo F, Ferrara C, Guerriero C, Nicolella D, Rossi A. Gridelli C, et al. J Thorac Oncol. 2007 Aug;2(8):758-61. doi: 10.1097/JTO.0b013e3180cc25b0. J Thorac Oncol. 2007. PMID: 17762344 Free article.

8

Erlotinib in patient with non-small cell lung cancer: significant symptomatic improvement within a few days but without change in chest X-ray.

Garfield D, Kashef G. Garfield D, et al. Lung Cancer. 2006 Mar;51(3):389-90. doi: 10.1016/j.lungcan.2005.10.009. Epub 2005 Dec 15. Lung Cancer. 2006. PMID: 16359750 No abstract available.

9

Erlotinib in lung cancer.

Pao W, Ladanyi M, Miller VA; Lung Cancer Oncogenome Group. Pao W, et al. N Engl J Med. 2005 Oct 20;353(16):1739-41; author reply 1739-41. N Engl J Med. 2005. PMID: 16240471 No abstract available.

10

Erlotinib or gefitinib for non-small-cell lung cancer.

Kaye FJ, Jantz MA, Dallas J. Kaye FJ, et al. N Engl J Med. 2011 Jun 16;364(24):2367; author reply 2368. doi: 10.1056/NEJMc1103918. N Engl J Med. 2011. PMID: 21675909 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

85 results

Results by year